After Neoadjuvant Chemo for Breast Cancer, Shorter Time To Surgery Better
Increasing time to surgery beyond four weeks is a modifiable risk factor for adverse oncologic outcomes after neoadjuvant chemotherapy for breast cancer, according to a new study presented at the 2020 annual meeting of the Society of Surgical Oncology (SSO), held virtually (abstract 12).